Detail

Basic Information Clinical Results Relationship Graph

Basic Information

Gene symbol	CD19	Synonyms	B4, CVID3	Type of gene	protein-coding
Chromosome	16	Map location	16p11.2	dbXrefs
Description	CD19 molecule

GTO ID	GTC1445
Trial ID	NCT01815749
Disease	Primary Cutaneous T-Cell Non-Hodgkin's Lymphoma \| Splenic Marginal Zone Lymphoma \| Burkitt Lymphoma \| Relapsed/Refractory Diffuse Large B-Cell Lymphoma \| Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue \| Follicular Lymphoma \| Intraocular Lymphoma \| Testicular Lymphoma \| Refractory Hairy Cell Leukemia \| Small Intestine Leiomyoma \| Mantle Cell Lymphoma \| Nodal Marginal Zone Lymphoma \| Grade III Lymphomatoid Granulomatosis \| Diffuse Small Cleaved Cell Lymphoma \| Macroglobulinemia \| Diffuse Large B-Cell Lymphoma \| Lymphoblastic Lymphoma \| Posttransplantation Lymphoproliferative Disease \| Marginal Zone Lymphoma \| Small Lymphocytic Lymphoma
Altered gene	CD19
Therapeutic/Target gene	Target gene
Therapy	CAR-T cell
Treatment	CD19 CAR-T cells
Generation	2nd
Phase	Phase1
Recruitment status	Active, Not Recruiting
Title	Genetically Modified T-cell Infusion Following Peripheral Blood Stem Cell Transplant in Treating Patients With Recurrent or High-Risk Non-Hodgkin Lymphoma
Year	2013
Country	United States
Company sponsor	City of Hope Medical Center
Other ID(s)	12224\|NCI-2013-00590\|P50CA107399

Vector information

Vector	lentivirus
Construct	CD19CAR-CD28-CD3zeta-EGFRt
Transgene/Inserted gene	scFv of the CD19-specific FMC63 monoclonal antibody; IgG4 hinge-CH2-CH3; signaling domains CD3ζ
Regulatory element	EF-1 promoter
Additional feature	EGFRt\|self-cleaving T2A sequence\|cytoplasmic domain of the CD3ζ chain\|CD28 costimulatory domain

Clinical Result

Cohort 1

Administration route	intravenous infusion
Donor type	Autologous
Pts	30
Age	Adult, Older_Adult
Lymph depletion	Yes
References	PMID: 27118452

Relationship Graph

Overview of Knowledge Graph